Plant & Quality
研究與發展Research & Development
High Barrier Generics
新聞發佈News & Media
/ Press Releases
TWi Announces Settlement with Takeda on Dexilant® Litigation
TWi Pharmaceuticals USA Announces the Receipt of State Sales Licenses from All 50 States in the U.S.
TWi Pharmaceuticals announces the first shipment of its generic product in the U.S. market.
TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan.
TWi Pharmaceuticals announces that its Board has appointed Ms. Tina Guilder as the President & CEO and Ms. Eva Ho as CFO to enhance the strategic move to commercialize its products in the U.S. market.
©Copyright 2013 安成國際藥業股份有限公司版權所有